BR112012004387A2 - anticorpos anticinas que se l igam a múltiplas quimiocinas cc. - Google Patents
anticorpos anticinas que se l igam a múltiplas quimiocinas cc.Info
- Publication number
- BR112012004387A2 BR112012004387A2 BR112012004387A BR112012004387A BR112012004387A2 BR 112012004387 A2 BR112012004387 A2 BR 112012004387A2 BR 112012004387 A BR112012004387 A BR 112012004387A BR 112012004387 A BR112012004387 A BR 112012004387A BR 112012004387 A2 BR112012004387 A2 BR 112012004387A2
- Authority
- BR
- Brazil
- Prior art keywords
- anticin
- chemokines
- antibodies
- bind
- anticin antibodies
- Prior art date
Links
- 102000001902 CC Chemokines Human genes 0.000 title 1
- 108010040471 CC Chemokines Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Rehabilitation Therapy (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23801509P | 2009-08-28 | 2009-08-28 | |
| PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012004387A2 true BR112012004387A2 (pt) | 2015-09-08 |
Family
ID=43628404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012004387A BR112012004387A2 (pt) | 2009-08-28 | 2010-08-27 | anticorpos anticinas que se l igam a múltiplas quimiocinas cc. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8313747B2 (enExample) |
| EP (1) | EP2470671B1 (enExample) |
| JP (2) | JP6109571B2 (enExample) |
| KR (1) | KR101778813B1 (enExample) |
| CN (1) | CN102782148B (enExample) |
| AU (1) | AU2010286516B2 (enExample) |
| BR (1) | BR112012004387A2 (enExample) |
| CA (1) | CA2771781C (enExample) |
| DK (1) | DK2470671T3 (enExample) |
| ES (1) | ES2531561T3 (enExample) |
| HR (1) | HRP20150162T1 (enExample) |
| IN (1) | IN2012DN01769A (enExample) |
| MX (1) | MX2012002427A (enExample) |
| PL (1) | PL2470671T3 (enExample) |
| PT (1) | PT2470671E (enExample) |
| SI (1) | SI2470671T1 (enExample) |
| SM (1) | SMT201500011B (enExample) |
| WO (1) | WO2011025962A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101778813B1 (ko) * | 2009-08-28 | 2017-09-14 | 리제너론 파마슈티칼스 인코포레이티드 | 다수의 ｃｃ 케모카인에 결합하는 항카인 항체 |
| DK2717941T3 (da) * | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Behandling af cancer |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| EP2763540A4 (en) * | 2011-09-09 | 2015-04-22 | Univ Yale | COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| JO3580B1 (ar) * | 2013-03-15 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لكيموكين elr+ cxc شامل |
| WO2014190316A1 (en) * | 2013-05-23 | 2014-11-27 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma |
| JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
| CN114044825A (zh) * | 2013-12-09 | 2022-02-15 | 爱乐科斯公司 | 抗Siglec-8抗体及其使用方法 |
| CA2939931C (en) | 2014-02-28 | 2025-04-22 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SIGLEC8 |
| CN106103479B (zh) | 2014-03-04 | 2019-12-24 | 彻莫马布有限公司 | 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体 |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| TWI576112B (zh) * | 2014-10-24 | 2017-04-01 | 國立陽明大學 | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用以保護胰臟及防止血糖升高的用途 |
| WO2016094481A1 (en) | 2014-12-09 | 2016-06-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| WO2016205567A1 (en) | 2015-06-17 | 2016-12-22 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| WO2018005519A2 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP7122002B2 (ja) * | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| IL269801B2 (en) * | 2017-04-05 | 2024-02-01 | Korea Res Inst Bioscience & Biotechnology | A fusion protein that activates NK cells, an NK cell, and a pharmaceutical preparation that includes them |
| MX2019013137A (es) | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar enfermedades oculares alergicas. |
| WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
| JP7543135B2 (ja) * | 2017-10-13 | 2024-09-02 | エー アンド ジー ファーマシューティカル，インコーポレイテッド | プロスタグランジンｆ２受容体阻害剤に対するモノクローナル抗体及びコンジュゲート、並びにそれらの使用 |
| US11891439B2 (en) | 2017-12-28 | 2024-02-06 | Astute Medical, Inc. | Antibodies and assays for CCL14 |
| US12352758B2 (en) | 2018-02-26 | 2025-07-08 | Cornell University | Quantitative biomarkers of EHV-1 susceptibility and protection |
| EP3791187A4 (en) * | 2018-05-11 | 2022-01-12 | Halcyon Therapeutics, Inc. | BINDING PROTEINS AND CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST GASP-1 GRANULES AND THEIR USE |
| JP7482866B2 (ja) | 2018-11-19 | 2024-05-14 | ビオラ・セラピューティクス・インコーポレイテッド | 生物学的治療薬による疾患処置方法およびデバイス |
| CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
| KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
| WO2021003284A1 (en) * | 2019-07-02 | 2021-01-07 | Astute Medical, Inc | Antibodies and assays for ccl14 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN113893331B (zh) * | 2020-07-06 | 2024-11-26 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
| US20230242623A1 (en) * | 2020-07-08 | 2023-08-03 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
| PE20231859A1 (es) * | 2020-10-16 | 2023-11-21 | Lanova Medicines Ltd | Anticuerpos monoclonales anti-ccr8 y sus usos |
| CN115598111B (zh) * | 2021-07-08 | 2025-03-25 | 南京大学 | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| HRP20050986A2 (en) | 2002-08-19 | 2006-11-30 | Abgenix | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| EP1567555A4 (en) * | 2002-11-27 | 2006-06-21 | Biogen Idec Inc | HUMANIZED ANTIBODIES AGAINST CHEMOTOXIC MONOCYTE PROTEINS |
| ES2321122T3 (es) * | 2004-12-21 | 2009-06-02 | Laboratoires Serono S.A. | Antagonistas de quimiocinas cc. |
| ES2453592T3 (es) * | 2007-08-02 | 2014-04-08 | Novimmune Sa | Anticuerpos anti-RANTES y métodos de uso de los mismos |
| KR101778813B1 (ko) * | 2009-08-28 | 2017-09-14 | 리제너론 파마슈티칼스 인코포레이티드 | 다수의 ｃｃ 케모카인에 결합하는 항카인 항체 |
-
2010
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko not_active Expired - Fee Related
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en not_active Ceased
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 HR HRP20150162TT patent/HRP20150162T1/hr unknown
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI2470671T1 (sl) | 2015-04-30 |
| US20130108640A1 (en) | 2013-05-02 |
| SMT201500011B (it) | 2015-03-05 |
| IN2012DN01769A (enExample) | 2015-06-05 |
| DK2470671T3 (en) | 2015-02-09 |
| KR101778813B1 (ko) | 2017-09-14 |
| WO2011025962A1 (en) | 2011-03-03 |
| US20150166647A1 (en) | 2015-06-18 |
| AU2010286516B2 (en) | 2016-10-06 |
| AU2010286516A2 (en) | 2012-06-14 |
| US8313747B2 (en) | 2012-11-20 |
| CA2771781A1 (en) | 2011-03-03 |
| JP2013503192A (ja) | 2013-01-31 |
| RU2012111820A (ru) | 2013-10-10 |
| PL2470671T3 (pl) | 2015-05-29 |
| EP2470671A1 (en) | 2012-07-04 |
| MX2012002427A (es) | 2012-08-03 |
| JP6109571B2 (ja) | 2017-04-05 |
| EP2470671B1 (en) | 2014-12-24 |
| ES2531561T3 (es) | 2015-03-17 |
| HRP20150162T1 (hr) | 2015-05-08 |
| EP2470671A4 (en) | 2013-04-03 |
| JP2016135783A (ja) | 2016-07-28 |
| KR20120091013A (ko) | 2012-08-17 |
| CN102782148B (zh) | 2016-04-20 |
| US20110059107A1 (en) | 2011-03-10 |
| AU2010286516A1 (en) | 2012-03-08 |
| CN102782148A (zh) | 2012-11-14 |
| PT2470671E (pt) | 2015-02-05 |
| US9005617B2 (en) | 2015-04-14 |
| CA2771781C (en) | 2019-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004387A2 (pt) | anticorpos anticinas que se l igam a múltiplas quimiocinas cc. | |
| PL2509409T3 (pl) | Myszy wytwarzające przeciwciała ciężkołańcuchowe | |
| PT2406284T (pt) | Anticorpos anti-bcma | |
| BRPI0916973A2 (pt) | anticorpos para ccr2 | |
| PT3409287T (pt) | Conjugados anticorpo fármaco (adc) que se ligam a proteínas 191p4d12 | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| AP2011005984A0 (en) | Antibodies specific to cadherin-17. | |
| BR112012002226A2 (pt) | anticorpos muc1. | |
| HUE042898T2 (hu) | Antitestek, amelyek kötnek CSF1R-t | |
| BR112012003780A2 (pt) | pregão semântico | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| EP2337798A4 (en) | SPECIFIC ANTIBODIES OF THE ASB | |
| IT1398793B1 (it) | Motociclo. | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI0912769A2 (pt) | anticorpos anti-pirb | |
| BRPI1009264A2 (pt) | composição adesiva melhorada. | |
| BRPI1013729A2 (pt) | compostos bisazo | |
| IT1400895B1 (it) | Motociclo. | |
| IT1401589B1 (it) | Zeoliti ad azione neuroprotettiva. | |
| BRPI1014266A2 (pt) | Compostos bisazo | |
| IT1397467B1 (it) | Tornio. | |
| FR2946591B1 (fr) | Sur-tapis eclairant. | |
| IT1396267B1 (it) | Etichettatrice. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: REGENERON PHARMACEUTICALS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07E | Notice of approval relating to section 229 industrial property law |